Biomaterials in percutaneous vertebroplasty

Aim. The purpose of this study is to reveal the safety and efficacy of biomaterials used in VPP in the treatment of vertebral spinal vertebral patients and primary vertebral tumors. Material and method. The retrospective study (December 2012-December 2015) included 21 patients admitted to the Sanado...
Ausführliche Beschreibung

Aim. The purpose of this study is to reveal the safety and efficacy of biomaterials used in VPP in the treatment of vertebral spinal vertebral patients and primary vertebral tumors. Material and method. The retrospective study (December 2012-December 2015) included 21 patients admitted to the Sanador Hospitals Department of Neurosurgery and Clinical Orthopedics-Traumatology and Osteoarticular TBC "Foişor", Bucharest, with VPP indication. Patients were diagnosed with vertebral spindles produced by vertebral metastases and primary vertebral tumors without compression in the vertebral canal. The diagnosis of these vertebral compressions has been established and confirmed by medical history, medical history, paraclinical investigation studies: column and face colorectal radiographs, native and contrast vertebral CT, 3D bone reconstruction and reconstruction, and native vertebral MRI contrast. Results. All VPPs have been technically successful, being well tolerated by patients, improved spinal algal symptomatology, rapid postoperative resumption of patient mobility. There were no major postoperative complications such as material migration into the canal, pulmonary embolism with material, infections, postoperative local haematomas, local or systemic reactions to VertaPlex®. All 21 patients were relieved with improved general condition without major postoperative complications. Clinical follow-up data over a 12-month period, detailed at 1, 3, 6, and 12 months after VPP and assessed with visual analogue scale, the Oswestry Disability Score Index and the Karnofsky Performance Scale have demonstrated, along with technical success, a significantly reduced rate of clinical pain, an improvement in disability and a real increase in quality of life and mobility in patients selected for study. Discussions. PMMA still prevails in choosing as a biomaterial in VPP but is not intrinsically degradable, which is a major barrier to wider applications. In order to eliminate the drawbacks of classical VPPs, new bone cements with biodegradable CPC potential have been generated, with a lower toxic potential than PMMA, and which can be improved by bone-stimulation-enhancing elements. Conclusions. VPP actually increases the quality of life of patients with vertebral spine caused by vertebral metastases and primary vertebral tumors. Biodegradability and biocompatibility, minimal exothermic reactions and insignificant contraction imply that biodegradable and mechanically assembled bone cements without graft rejection will be the future of VPP biomaterials. Ausführliche Beschreibung